{
  "ticker": "HALO",
  "company_name": "Halozyme Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03979066",
      "title": "Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Pancreatic Ductal Adenocarcinoma",
      "start_date": "2019-11-01",
      "completion_date": "2019-11-03",
      "enrollment": 0,
      "sponsor": "Gulam Manji"
    },
    {
      "nct_id": "NCT02753595",
      "title": "Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Metastatic Breast Cancer",
      "start_date": "2016-07-13",
      "completion_date": "2019-08-16",
      "enrollment": 0,
      "sponsor": "Eisai Inc."
    }
  ],
  "summary": {
    "total_trials": 2,
    "by_phase": {
      "PHASE2": 1,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "TERMINATED": 2
    },
    "active_trials": 0,
    "completed_trials": 0,
    "conditions": [
      "Metastatic Breast Cancer",
      "Pancreatic Ductal Adenocarcinoma"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:11.812909",
    "search_query": "Halozyme Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Halozyme+Therapeutics,+Inc."
  }
}